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ABSTRACT
Background Intracranial in-stent hyperplasia is a
stroke-associated complication that requires routine
surveillance.
Objective To compare the results of in vivo
experiments to determine the accuracy and precision of
in-stent hyperplasia measurements obtained with
modiﬁed C-arm contrast-enhanced, cone-beam CT
(CE-CBCT) imaging with those obtained by ‘gold
standard’ histomorphometry. Additionally, to carry out
clinical analyses comparing this CE-CBCT protocol with
digital subtraction angiography (DSA).
Methods A non-binned CE-CBCT protocol (VasoCT)
was used that acquires x-ray images with a small ﬁeld-
of-view and applies a full-scale reconstruction algorithm
providing high-resolution three-dimensional (3D) imaging
with 100 mm isotropic voxels. In an vivo porcine model,
VasoCT cross-sectional area measurements were
compared with gold standard vessel histology. VasoCT
and DSA were used to calculate in-stent stenosis in 23
imaging studies.
Results Porcine VasoCT cross-sectional stent, lumen,
and in-stent hyperplasia areas strongly correlated with
histological measurements (r2=0.97, 0.93, 0.90;
slope=1.14, 1.07, and 0.76, respectively; p<0.0001).
Clinical VasoCT percentage stenosis correlated well with
DSA percentage stenosis (r2=0.84; slope=0.76), and the
two techniques were free of consistent bias (Bland–
Altman, bias=3.29%; 95% CI −14.75% to 21.33%).
An illustrative clinical case demonstrated the advantages
of VasoCT, including 3D capability and non-invasive IV
contrast administration, for detection of in-stent
hyperplasia.
Conclusions C-arm VasoCT is a high-resolution 3D
capable imaging technique that has been validated in an
animal model for measurement of in-stent tissue growth.
Successful clinical implementation of the protocol was
performed in a small case series.
INTRODUCTION
Intracranial stenting is an effective therapy for spe-
ciﬁc cerebrovascular disorders, including medical
treatment-resistant atherosclerosis,1 cerebral aneur-
ysms,2–7 and arterial dissections.8 9 However,
in-stent tissue growth, termed neointimal hyperpla-
sia (NIH) and in-stent restenosis (ISR), is a signiﬁ-
cant long-term stroke-associated complication that
requires routine surveillance of vessel anatomy.10 11
Catheter-based digital subtraction angiography
(DSA) is the imaging standard for NIH/ISR
detection; however, DSA relies on two-dimensional
(2D) vascular representations that may over- or
underestimate asymmetric tissue growth.12
Magnetic resonance angiography (MRA) and com-
puted tomography angiography (CTA) are non-
invasive 3D capable alternatives to DSA, but lack
sufﬁcient spatial resolution and suffer from
implant-associated artifacts that diminish reliable
visualization of in-stent vessel hyperplasia.13–17
Thus, a minimally invasive 3D capable, cross-
sectional imaging technique with resolution to
detect NIH/ISR would circumvent the former lim-
itations, better inform clinicians, and potentially
improve patient care.
Flat-detector C-arm cone-beam CT (CBCT) has
shown to be a valuable imaging technique, provid-
ing in situ cross-sectional imaging with CT-like
quality.18–22 CBCT data are generated from a large
series of x-ray images acquired during a rotational
sweep of the x-ray source and the detector around
the patient. Generally, pixel binning of the x-ray
images is performed to improve the signal-to-noise
ratio, allowing for soft tissue contrast. VasoCT is a
modiﬁcation to the standard CBCT protocol that
acquires x-ray images without pixel binning and a
small ﬁeld of view. As a result, VasoCT data can be
generated with isotropic spatial resolution up to
67 mm at a trade-off of the signal-to-noise ratio.
VasoCT has demonstrated detailed visualization of
cerebrovascular stents,23 non-alloy microcannu-
las,24 and micro-sized arteriovenous malforma-
tions.25 Although qualitative evaluation of VasoCT
has produced promising results, quantitative evalu-
ation of the accuracy and precision of in vivo mea-
surements has not been performed.
Herein, non-binned, high-resolution, contrast-
enhanced VasoCT was quantitatively evaluated and
compared with ‘gold standard’ vessel histology in a
porcine model of in-stent tissue growth.
Subsequently, gold standard clinical DSA measure-
ments from a small patient group were compared
with VasoCT to evaluate the accuracy of this proto-
col in the detection of NIH/ISR.
MATERIALS AND METHODS
In vivo animal experiment
Experimental design
All experiments were approved by our institutional
animal care and use committee. An in vivo porcine
model was used to quantitatively evaluate the
ability of VasoCT to measure in-stent tissue growth
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relative to gold standard histomorphometry.26 27 Brieﬂy, an
adult Yorkshire swine (60 kg) was started on daily aspirin
(81 mg) 3 days before the procedure. On day 0, the pig was
anesthetized (intramuscular injection of tiletamine/zolazepam
5 mg/kg, xylazine 2.5 mg/kg, glycopyrrolate 0.01 mg/kg, and
ketamine 2.5 mg/kg; followed by mechanical ventilation with
2% isoﬂurane), access was obtained via the right femoral artery,
four distinct arterial areas were identiﬁed within the bilateral
subscapular (pre-implant diameter of 2.1 mm) and right
common carotid (pre-implant diameter of 4.3 mm) arteries by
DSA, 5–10 mm of each area was damaged with a cutting
balloon to intensify the hyperplasic response and then stented
to cover the injured segment with four non-overlapping self-
expanding intracranial stents (Wingspan, n=3: 4 mm×15 mm,
4 mm×20 mm, 4.5 mm×20 mm, Neuroform, n=1: 3.5
mm×15 mm; Stryker Neurovascular, Fremont, California,
USA). The largest-diameter stent was used in the right common
carotid artery, and the remaining stents were placed in the bilat-
eral subscapular arteries. During the procedure an IV heparin
bolus (100 U/kg) was administered and anticoagulation was
monitored to maintain an activated clotting time >250 s. After
the procedure, the pig was recovered alive and returned to the
animal facility. On day 42, the daily aspirin was stopped. On
day 49, the pig was anesthetized, access obtained via the left
femoral artery, and DSA and VasoCT images were acquired (see
‘Image acquisition’ section). After image acquisition the animal
was immediately killed, perfused under physiological pressure
with saline followed by 4% paraformaldehyde, and stented
vessels were explanted and prepared for histological analysis.
Image acquisition
VasoCT and DSA images were acquired using a monoplane
neuroangiographic unit equipped with a 1920×2480 cesium
iodide−amorphous silicon ﬂat panel detector covering an area
of about 30×40 cm (AlluraXper FD20; Philips Healthcare,
Best, the Netherlands). DSA images were acquired using stand-
ard angiographic techniques. The VasoCT protocol acquires the
projection images without pixel binning and with a reduced
Figure 1 In-stent tissue growth visualized with digital subtraction angiography (DSA), VasoCT, and histology. (A) DSA image of stented right distal
subscapular artery demonstrating in-stent tissue growth secondary to an arterial dissection (arrow); note proximal and distal stent markers (arrow
heads), contrast ﬁlled lumen (asterisk), and gradual taper of in-stent tissue growth between vessel lumen and stent marker. (B) VasoCT image of the
same artery as in A. (C) Representative and corresponding cross-sectional VasoCT (left) and histological (right) images; note signiﬁcant in-stent
tissue growth with distal to proximal taper; box colors correspond to approximate location of colored lines in (B). CE-CBCT, contrast-enhanced,
cone-beam CT.
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detector format of 22 cm×22 cm, which allows for higher
spatial resolution than conventional CBCT.23 28 The motorized
frontal C-arm was used to acquire 620 projection images over a
200° arc (rotation time, 20.7 s) at 80 kVp and a total of
260 mAs. During acquisition, 15% iodinated contrast in normal
saline (Isovue 350; Bracco Diagnostics, Princeton, New Jersey,
USA) was injected intra-arterially via a 6 Fr catheter (Envoy,
Cordis Endovascular, New Brunswick, New Jersey, USA) posi-
tioned at the origin of the subscapular or common carotid
artery at a rate of 2.5 mL/s for 23 s with a 3 s start delay. The
source projection frames were acquired in a 10162 matrix cover-
ing an approximate 155×155 mm2 ﬁeld of view, yielding a
pixel size of 0.154 mm. The maximum 3D ﬁeld of view was
106 mm in each dimension. All VasoCT images were recon-
structed with a 5123 matrix centered about the stent, resulting
in an isotropic spatial resolution of about 0.1×0.1×0.1 mm3.
Postprocessing steps included gain calibration, scatter correction,
white compression inversion, water beam-hardening correction,
and Parker weighting. VasoCT datasets were further processed
to reformations perpendicular to the stent region with a section
thickness range of 0.067–0.1 mm. The radiation dose of a single
VasoCT is about 49 mGy.23
Histological preparation
Explanted vessels were embedded in epoxy resin, and a high-
resolution radiograph was acquired to co-register histological
sectioning with previously acquired VasoCT data. The embed-
ded vessels were then sectioned with a Buehler Diamond saw,
lightly sanded, polished, stained (1% toluidine blue) and imaged
using an Olympus AX90 microscope ﬁtted with a Q-Color5
5MP digital camera system. Final vessel sections were about
60 μm thick.
Cross-sectional analysis
VasoCT cross-sectional images from each vessel were registered
with corresponding histological sections accounting for section
thickness, interslice distance, and distance from stent markers.
A best-ﬁt polygon was placed using ImageJ (NIH, Bethesda,
Maryland, USA) to calculate in-stent and lumen area measure-
ments for each VasoCT and histological image. For in-stent area
measurements, a polygon point was placed at the luminal lateral
surface of each stent strut; for luminal area measurements,
numerous points were placed along the vessel’s luminal surface.
In-stent hyperplasia areas were calculated by subtracting each
section’s luminal area from its in-stent area. Correlation
between VasoCT data and histology was established using a total
of 26 independent measurements performed across the four
implanted stents.
Statistical analysis
VasoCT and histology-derived measurements were compared
with linear regression.
All statistical analyses were conducted with Graphpad Prism (V.6).
Clinical evaluation
Patients
This retrospective study was approved by our institutional
review board. Patients (n=19) returning to our institution for
Figure 2 Cross-sectional VasoCT in-stent area measurements strongly correlate with histology measurements. (A) Linear regression of
cross-sectional stent areas measured by VasoCT and histology (r2=0.97, slope=1.14±0.04, x intercept=0.69, y intercept=−0.78±0.28). (B) Same as
A; lumen areas (r2=0.93, slope=1.07±0.06, x intercept=−0.82, y intercept=−0.87±0.32). (C) Same as A, B; in-stent hyperplasia areas (r2=0.90,
slope=0.76±0.05, x intercept=0.79, y intercept=−0.60±0.13). n=26 and p<0.0001 for A–C. (D) Representative VasoCT (top) and histology-derived
images (bottom) demonstrating cross-sectional measurement technique (see ‘Methods’); left, stent area; right, lumen area. Line thickness was
enhanced for visualization. CE-CBCT, contrast-enhanced, cone-beam CT.
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post-stent intracranial vessel imaging examinations were
included in the analysis (mean time between stent placement
and follow-up examination=251 days, range=155–575 days).
Only patients receiving both DSA and VasoCTevaluations at the
time of post-stent follow-up were included; all other patients
were excluded. All patients received intracranial stent or ﬂow
diverter placement for the treatment of atherosclerotic disease
(Pharos Vitesse, Micrus Endovascular Corp, San Jose,
California, USA, n=2; Wingspan, n=6; Neuroform, n=1; or
aneurysms (Pipeline embolization device, Covidien/eV3,
Mansﬁeld, Massachusetts, USA, n=10). Stented intracranial
vessels included the internal carotid artery (ICA; n=8), middle
carotid artery (MCA; n=8) and vertebral arteries (n=4). Three
patients returned twice for 6-month and 1-year follow-up exam-
inations; both time points were included in the analysis. One
patient had bilateral internal carotid artery stents placed; both
stents were used for analysis. One patient was excluded owing
to signiﬁcant motion artifact, which limited the VasoCT image
evaluation. In total, 23 independent imaging studies were avail-
able for analysis.
Image acquisition
The VasoCT imaging was performed similarly to the protocol
used in the in vivo animal experiments; except, 20% iodinated
contrast (Isovue-250; Bracco Diagnostics, Princeton, New
Jersey, USA) was injected intra-arterially. Catheter type, location,
and the injection parameters were used as previously reported.23
In two cases, contrast was administered intravenously using pre-
viously reported injection parameters,29—namely, 100 mL of
contrast injected at 4 mL/s through an 18 g IV catheter placed in
the right cubital vein. DSA was carried out using standard angio-
graphic techniques.
Image analysis
VasoCTand DSA percentage stenosis was calculated from images
of the vessel aligned along its long axis, as previously reported.30
If multiple views of the stented segment were available, DSA
measurements were performed using the best possible image (eg,
zoomed and oblique) acquired by the neurointerventional radi-
ologist. Two luminal measurements were made per vessel for
each imaging modality: the minimum in-stent diameter (Din-stent)
as a measure of NIH/ISR and the proximal non-stented healthy
vessel diameter (Dproximal) for normalization. The measurements
for each vessel were made at the same location (approximate) for
both VasoCT and DSA. If the proximal non-stented vessel was
inadequate for analysis (eg, diseased segment), the distal non-
stented healthy vessel diameter was used for normalization
(n=3). Percentage stenosis was calculated by:
Stenosisð%Þ ¼ 1 Din-stent
Dproximal
 
 100 ð1Þ
Statistical analysis
VasoCT and DSA-derived measurements were compared with
linear regression and the Bland–Altman test.31 All statistical ana-
lyses were conducted with Graphpad Prism (V.6).
RESULTS
In vivo animal experiment
When the porcine model was used, consisting of arterial
damage, stenting, and a post-stent incubation period, a substan-
tial area of in-stent tissue growth was created and visualized
(ﬁgure 1A,B). The in-stent tissue growth, recognized as the
non-contrast/hypodense area between the stent struts and
contrast-ﬁlled lumen, was found to gradually taper in the prox-
imal direction along the artery (ﬁgure 1B,C). To quantify the
area of in-stent tissue growth, VasoCT vessel cross-sections were
created and spatially matched to histological sections (ﬁgure
1C). VasoCT stent, lumen, and in-stent tissue growth area mea-
surements were calculated from each cross-section correspond-
ing to the histological sections, which is the gold standard for
quantifying in-stent tissue growth (ﬁgure 2A–C). VasoCT stent,
lumen, and in-stent tissue growth areas strongly correlated with
histology-derived measurements (r2=0.97, 0.93, 0.90, respect-
ively; p<0.0001). Moreover, the slopes of these relationships,
which were between 0.9 and 1.14, and y intercepts, which were
all <1 mm2, indicate an almost one-to-one relationship between
VasoCT and histology, particularly for the stent area measure-
ment, which was nearly identical between the two measurement
methods. The non-zero y intercepts in ﬁgures 2B,C indicate a
small bias between VasoCT and histology measurements of
lumen area and in-stent tissue growth area. This bias is due to a
slight but consistent overestimation of the VasoCT-calculated
lumen area as compared with histology (ﬁgure 3A). This over-
estimation results in an underestimation of in-stent tissue
growth area measured by VasoCT, and a decreased sensitivity
for its detection (ﬁgure 2C,B). However, the threshold for
detection of VasoCT is low and can visualize in-stent tissue
Figure 3 VasoCT overestimates cross-sectional lumen area relative to
histology, resulting in decreased hyperplasia detection.
(A) Representative VasoCT (left) and histological (right) mirror images
from an identical arterial segment (approximate); stent, lumen, and
in-stent hyperplasia are clearly visible, note increased VasoCT lumen
area relative to histology lumen area. (B) VasoCT (left), histology (right);
note thin circumferential area of hyperplasia on histology (arrow) not
visible on VasoCT. CE-CBCT, contrast-enhanced, cone-beam CT.
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growth ≥0.79 mm2 (ﬁgure 2C). VasoCT lumen area overesti-
mation is probably due to partial volume errors, but vessel
motion, noise, and contrast pulsatility may also contribute.
To move to the clinical measurements presented below, we
compared the percentage stenosis of each device implanted in
the pig model measured by DSA and by VasoCT. The average
difference between these two techniques was 9.2%. Using a
non-parametric, paired t test we found no difference between
the DSA and VasoCT percentage stenosis calculations. When
compared by linear regression, the coefﬁcient of determination
was 0.98 and the slope was signiﬁcantly different from zero
(p=0.013).
Clinical evaluation
The former experiments conﬁrm that quantiﬁcation of in-stent
tissue growth by VasoCT strongly correlates with gold standard
histology in an animal model (see above); therefore, the next
logical step was to evaluate VasoCT against the clinical NIH
detection standard, DSA. To perform this analysis, intrapatient
VasoCT and DSA in-stent percentage stenosis measurements
were calculated and compared (ﬁgures 4A–D). VasoCT measure-
ments correlated well with DSA measurements using a linear
regression analysis (r2=0.84, p<0.0001; ﬁgure 4C). Bland–
Altman analysis showed that VasoCT and DSA are equivalent
and free of systematic bias when measuring patient in-stent NIH
(bias=3.29%, SD of bias=9.20, 95% CI −14.75% to 21.33%;
ﬁgure 4D).
Illustrative case
Brieﬂy, a septuagenarian presented with left sided numbness,
investigation, including MRI and DSA, showed right-sided
temporal-parietal infarct secondary to right-sided MCA stenosis
(>70%) (ﬁgure 5A, top image). To treat the symptomatic
patient an intracranial stent was placed in the right MCA, which
completely resolved the stenotic area as visualized with postin-
tervention imaging (ﬁgure 5A, middle image, ﬁgure 5B).
Six-month post-stent follow-up DSA imaging showed a fully
patent in-stent vessel lumen (ﬁgure 5A, bottom image).
However, concurrent VasoCT imaging detected an area of
in-stent NIH (ﬁgure 5C). The area of NIH was visualized using
cross-sectional vessel reconstructions available with VasoCT, but
not with DSA. After the VasoCT acquisition, an oblique DSA
image was acquired using projection angles derived from
VasoCT data and resulted in DSA detection of the in-stent
hyperplasia (ﬁgure 5D). This result is consistent with the sugges-
tion that VasoCTand DSA are equivalent for in-stent NIH quan-
tiﬁcation when similarly oriented, but VasoCT provides better
detection because DSA is dependent on the acquisition angle.
Figure 4 VasoCT is equivalent to the clinical standard, digital subtraction angiography (DSA), in measuring percentage stenosis. (A) Representative
DSA image (frontal oblique projection) acquired at 6-month follow-up after treatment of an anterior choroidal artery aneurysm using a Pipeline
embolization device. Proximal and distal ends of the stented segment are indicated (arrow heads). DSA demonstrates mild in-stent hyperplasia
(arrows) of the distal internal carotid artery and proximal middle cerebral artery. (B) VasoCT data reformatted to a different orientation than DSA
(oblique submental projection) in order to fully appreciate the stented segment (arrow heads) and areas of hyperplasia (arrows). Owing to the
isotropic voxels of the VasoCT dataset, images can be reformatted to any orientation without loss of resolution (see insets showing vessel
cross-sections). (C) Linear regression of in-stent percentage stenosis measured by VasoCT and DSA (r2=0.84, slope=0.76±0.07, x intercept=−16.10,
y intercept=12.19±3.06). (D) Bland–Altman plot—difference between percentage stenosis measured by VasoCT and DSA for each examination
plotted against their mean (95% CIs (−14.75% to 21.33%); bias=3.29%, SD of bias=9.20%. n=23 and p<0.0001 for C, D). CE-CBCT,
contrast-enhanced, cone-beam CT.
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Importantly, the VasoCT images contained within ﬁgure 5 were
acquired using intravenously administered contrast, providing
support for its potential as a non-invasive alternative to DSA.
DISCUSSION
In-stent NIH of intracranial vessels is a serious long-term
post-stent complication that requires routine surveillance of
vessel anatomy.10 11 DSA is the clinical standard for in-stent
NIH detection. However, DSA is limited by its inherent 2D
nature, which may result in missed diagnoses.12 MRA and CTA
are non-invasive 3D capable alternatives to DSA, but both lack
sufﬁcient spatial resolution and require advanced approaches to
reduce implant artifacts and reliably visualize in-stent NIH.13–
16 32 33 The advent of a clinical imaging technique which could
circumvent these limitations would result in substantial improve-
ment in patient diagnosis and care. We hypothesized that
VasoCT, with its high spatial resolution and isotropic 3D cap-
ability might be a diagnostically better alternative for in-stent
intracranial NIH detection.17 29 To test this hypothesis, VasoCT
was validated in an animal model of in-stent tissue growth and
in post-stent neurointerventional patients. When the animal
model was used, quantitative VasoCT was found to strongly
correlate with gold standard histological measurements, includ-
ing stent, lumen, and in-stent tissue growth areas. However,
consistent VasoCT lumen overestimation, due to partial volume
errors, vessel movement during acquisition, backscatter, and
noise, resulted in decreased in-stent tissue growth measurements
and an increased detection threshold relative to microscopic
examination of the explanted vessels. According to the linear
model, the in-stent tissue growth should have an area of at least
0.79 mm2 in order to be detected by VasoCT. Despite this
minor difference, the animal experiments proved that VasoCT
vessel reconstructions reliably recapitulate and accurately
measure long-term in-stent vascular pathology in a living bio-
logical organism, complete with cardiac pulsations, overlying
soft and boney tissue, and vessel anatomy. Although the quanti-
tative evaluation was performed using only a single animal, the
four stented vessel segments used provided 26 independent
measurements with sufﬁcient variability in vessel size and degree
of NIH for reliable analysis.
Given these encouraging results, it was no surprise that
VasoCT also proved useful in the clinic. For instance, in our
patient group VasoCTwas as effective as DSA, the current clin-
ical standard, at measuring in-stent percentage stenosis in
Figure 5 Comparison of VasoCT with digital subtraction angiography (DSA) for the detection of in-stent hyperplasia. (A) Intra-arterial DSA images
of a septuagenarian with left-sided numbness, pretreatment DSA image showing >70% stenosis of right middle cerebral artery (arrow, top image),
post-stent DSA image showing complete recanalization of stenotic vessel lumen (arrow, middle image), 6-month post-stent follow-up demonstrating
a fully patent stent lumen (bottom image). (B) Intravenous VasoCT images post-stent demonstrating a fully patent stent lumen with good stent
vessel apposition (left, vessel long axis; right, vessel cross-section). (C) Intravenous VasoCT 6-month post-stent follow-up showing an extended
(arrow) crescent shaped (arrow head) hypodense area consistent with in-stent restenosis (ISR) (left, long axis; right, cross-section). (D) 6-Month
post-stent follow-up DSA image taken with C-arm rotationally aligned with viewing coordinates of image in C. Note an extended area of ISR can
now be seen (arrow), similar in size and shape to that found in C.
Basic science
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follow-up examinations to evaluate in-stent NIH. Bland–Altman
analysis showed that in four cases the agreement between the
two measurements was reduced, with differences ranging from
12% to 26%. In these cases, VasoCT showed a higher percent-
age stenosis which was not visible on DSA owing to asymmetric
NIH and non-optimal acquisition angle. Further, no systematic
bias was found between the two measurement techniques. Thus,
in our study VasoCT is equivalent to DSA, which agrees with
previously reported ﬁndings34; however, for detection of eccen-
tric in-stent NIH, 3D capable VasoCT appears to be better than
DSA since these stenoses might be overlooked in cases of non-
optimal angulation of the x-ray system (see ‘Illustrative case’,
ﬁgure 5). Furthermore, there is strong preliminary evidence that
CBCT acquired with intravenously administered contrast is
effective for the detection of in-stent NIH, afﬁrming its poten-
tial use as a non-invasive alternative to DSA17 29 34 35 (ﬁgure 5).
However, validation of these results in a larger sample is
needed. If conﬁrmed, the clinical advantages of VasoCT for the
evaluation of post-stent NIH would be numerous, as IV
contrast-administered VasoCT (IV-VasoCT) would substantially
reduce time, cost, and procedural complications related to inva-
sive DSA. Furthermore, IV-VasoCT would reduce radiation
exposure for the patient and interventionist, by requiring less
radiation and freeing healthcare personnel from the patient’s
side during the examination.
There was very little in-stent stenosis in the ﬂow diverter
cases (mean in-stent stenosis 25%, range 3.5–53%). This is in
agreement with published results, where in-stent stenosis is rare
and generally mild.3 36–38 The ISR was more severe in cases
where stenting was performed to treat intracranial atheroscler-
osis (mean ISR 49%, range 10–82%); which again reﬂects pub-
lished values.39–42 In the animal experiment, we found that the
sensitivity of VasoCT is better for larger areas of NIH.
Translating this ﬁnding to our clinical series, the correlation
improved when we excluded the aneurysm cases and only com-
pared the more severe ISR from intracranial atherosclerosis
(R2=0.90, p<0.0001).
Although the substantial beneﬁts of VasoCT, relative to DSA,
are evident, VasoCT is not without its own drawbacks. For
example, VasoCT image interpretation is limited by metal arti-
facts and reduced ﬁeld of view that does not capture the entire
cerebrovasculature; however, techniques to reduce metal arti-
facts are improving.32 33 Additionally, although VasoCT can reli-
ably detect and measure in-stent tissue growth, it is unable to
determine the exact nature of the underlying vascular pathology.
The technique requires a compliant patient who can endure a
20 s study without moving. Finally, as with CTA, VasoCT with
contrast administered IV requires careful consideration of the
patient’s cardiac and renal function to determine tolerance to a
relatively large bolus.
All things considered, VasoCT is an effective imaging tech-
nique for the evaluation of post-stent intracranial NIH and has
great clinical potential. Study limitations include a small patient
group with heterogeneous stented disorders. Larger clinical
trials to deal with these limitations and to evaluate further the
potential of IV-VasoCT as a non-invasive and diagnostically
better alternative to DSA are needed.
CONCLUSIONS
Non-binned C-arm contrast-enhanced cone-beam CT, a high-
resolution 3D capable imaging technique, has been validated
against histomorphometry to reliably quantify in-stent tissue
growth. Preliminary clinical data suggest that calculation of per-
centage stenosis using either VasoCT or DSA provides similar
results. A large-scale clinical trial is needed to further evaluate
the effectiveness of VasoCTwith IV-administered contrast.
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